287 related articles for article (PubMed ID: 26317313)
41. Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy.
Yang L; Shen M; Qiu Y; Tang T; Bu H
Breast; 2022 Aug; 64():1-6. PubMed ID: 35462343
[TBL] [Abstract][Full Text] [Related]
42. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
Zeng Y; Gao W; Chen X; Shen K
Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279
[TBL] [Abstract][Full Text] [Related]
43. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
[TBL] [Abstract][Full Text] [Related]
44. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup.
Shekhar MP; Kato I; Nangia-Makker P; Tait L
Oncotarget; 2013 Feb; 4(2):231-41. PubMed ID: 23548208
[TBL] [Abstract][Full Text] [Related]
45. Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging.
Vermeulen JF; van der Wall E; Witkamp AJ; van Diest PJ
Cell Oncol (Dordr); 2013 Jul; 36(4):333-40. PubMed ID: 23744486
[TBL] [Abstract][Full Text] [Related]
46. Discordant HER2 immunohistochemical expression and gene amplification in ductal carcinoma in situ - evaluating HER2 in synchronous in-situ and invasive carcinoma.
Hui Y; Lu S; Wang H; Resnick MB; Wang Y
Histopathology; 2019 Jan; 74(2):358-362. PubMed ID: 30117181
[No Abstract] [Full Text] [Related]
47. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
[TBL] [Abstract][Full Text] [Related]
49. The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS).
Al-Kawaz A; Ali R; Toss MS; Miligy IM; Mohammed OJ; Green AR; Madhusudan S; Rakha EA
Breast Cancer Res Treat; 2021 Nov; 190(1):39-51. PubMed ID: 34406589
[TBL] [Abstract][Full Text] [Related]
50. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion.
Wan ZB; Gao HY; Wei L; Zhang AQ; Zhang JY; Wang Y; Wang DD; Zhang Y
Medicine (Baltimore); 2018 Nov; 97(44):e13055. PubMed ID: 30383678
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ.
Tamura N; Tsuda H; Yoshida M; Hojo T; Akashi-Tanaka S; Kinoshita T; Sugihara K
Breast Cancer; 2016 May; 23(3):510-8. PubMed ID: 25666939
[TBL] [Abstract][Full Text] [Related]
52. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
53. Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.
Guerini-Rocco E; Bellerba F; Concardi A; Taormina SV; Cammarata G; Fumagalli C; Guerrieri-Gonzaga A; Macis D; Del Fiol Manna E; Balladore E; Cannone M; Veronesi P; Fusco N; Bonanni B; Viale G; Barberis M; Gandini S; Lazzeroni M
Eur J Cancer; 2024 May; 203():114063. PubMed ID: 38615592
[TBL] [Abstract][Full Text] [Related]
54. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
55. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
[TBL] [Abstract][Full Text] [Related]
56. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.
Schandiz H; Park D; Kaiser YL; Lyngra M; Talleraas IS; Geisler J; Sauer T
Breast Cancer Res Treat; 2023 Sep; 201(2):329-338. PubMed ID: 37453021
[TBL] [Abstract][Full Text] [Related]
57. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast.
Park SS; Kim JE; Kim YA; Kim YC; Kim SW
Histopathology; 2005 Dec; 47(6):625-30. PubMed ID: 16324201
[TBL] [Abstract][Full Text] [Related]
58. Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ.
Wu L; Zhao Y; Lin P; Qin H; Liu Y; Wan D; Li X; He Y; Yang H
BMC Med Imaging; 2021 May; 21(1):84. PubMed ID: 34001017
[TBL] [Abstract][Full Text] [Related]
59. CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in situ.
Morita M; Yamaguchi R; Tanaka M; Tse GM; Yamaguchi M; Kanomata N; Naito Y; Akiba J; Hattori S; Minami S; Eguchi S; Yano H
Cancer Med; 2016 Jul; 5(7):1607-18. PubMed ID: 27061242
[TBL] [Abstract][Full Text] [Related]
60. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
